Ahead of the 14th WTO Ministerial Conference (MC14), trade associations representing the pharmaceutical industry provide a perspective on how WTO Members can a roadmap to strengthen global health through meaningful trade policies.
Read more
In new research commissioned by IFPMA, Airfinity has determined that an additional investment of 1% of GDP toward domestic general government health expenditure in low- and middle-income countries (LMICs) would amount to a US$ 310 billion additional investment, representing a 33% increase in current spending. This research is a response to the UHC 2030 action agenda...
Read more
Non-communicable diseases (NCDs), such as diabetes, cardiovascular, renal and metabolic diseases, cancer, chronic respiratory diseases, mental health and neurological diseases, are one of the greatest global health and economic threats we face in our lifetime. Since 2000, global deaths due to NCDs have increased rapidly, even as deaths due to communicable diseases have declined. The...
Read more
On 17 February 2025, IFPMA delivered a statement during the 13th Intergovernmental Negotiating Body (INB 13).
Read moreWhat is an HTA and how is it used? Health technology assessment (HTA) is a multidisciplinary process that uses explicit methods to determine the value of a health technology at different points in its lifecycle. The purpose is to inform decision-making in order to promote an equitable, efficient, and high-quality health system. An HTA agency...
Read more
On 8 February 2025 at the EB156 in Geneva, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA), Global Self-Care Federation (GSCF), and International Hospital Federation (IHF) delivered a statement on Agenda Item 22: Climate change and health.
Read moreOn 7 February 2025 at the EB156 in Geneva, the Fight the Fakes Alliance delivered a statement on substandard and falsified medical products. IFPMA is a member of Fight the Fakes Alliance.
Read moreOn 6 February at the EB156, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA), Global Self-Care Federation (GSCF), International Pharmaceutical Federation (FIP), International Alliance of Patients’ Organizations (IAPO), and International Generic and Biosimilar Medicines Association (IGBA) delivered a statement on Agenda Item 15: WHO’s work in health emergencies.
Read moreOn 5 February at the EB156 in Geneva, IFPMA delivered a statement on non-communicable diseases (NCDs).
Read morePharmacy-mediated substitution is a framework permitting substitution of medicines at the retail pharmacy without the consent of the prescribing physician. In this paper, IFPMA outlines a set of principles that can guide pharmacy-mediated substitution. While the principles are intended for the awareness of pharmacists, they can also relate to other healthcare providers, regulators, payers, and those involved in formulary and procurement decision-making.
Read more
An aging population, the rise of antimicrobial resistance, and the ongoing threat of infectious and chronic diseases are placing immense pressure on our societies. In this context, a paradigm shift from healthcare systems that focus on treating people when they are sick, to a prevention approach is a necessity to guarantee the efficiency and long-term...
Read more
This blog highliths that a lifelong vaccination approach can be a critical tool to reduce the strain on healthcare systems, protect vulnerable populations, and support economic stability.
Read more